

- 13) Shota Hamada, Shiro Hinotsu, Katsuhito Hori, Hiroshi Furuse, Takehiro Oikawa, Junichi Kawakami, Seiichiro Ozono, Hideyuki Akaza, and Koji Kawakami. The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study. *Supportive Care in Cancer*, 20:813-820, 2012.
- 14) Makoto Kishida, Kazunori Ishige, Tomohisa Horibe, Noriko Tada, Nobutaka Koibuchi, Junichi Shoda, Kiyoshi Kita, and Koji Kawakami. Orexin 2 receptor as a potential target for the immunotoxin and antibody-drug conjugate cancer therapy. *Oncology Letters*, 3: 525-529, 2012.
- 15) Hanae Ueyama, Tomohisa Horibe, Shiro Hinotsu, Tomoaki Tanaka, Takeomi Inoue, Hisashi Urushihara, Akira Kitagawa, and Koji Kawakami. Chromosomal variability of human mesenchymal stem cells cultured under hypoxic condition. *Journal of Cellular and Molecular Medicine*, 16: 72-82, 2012.
- (著書)
- 16) 川上 浩司. 「医療政策、医療技術評価、リテラシー：先制医療の視点から。」日本の未来を拓く医療. 井村裕夫編集. 診断と治療社, pp107-115, 2012.
- 17) 川上 浩司. 「バイオ医薬品の薬事申請とレギュラトリーサイエンス」新機能抗体開発ハンドブック (次世代抗体創製から産業への展開まで). エヌ・ティー・エス, pp561-567, 2012.
- (和文)
- 18) 川上 浩司. 比較有効性研究. 最新医学, 67 (10) 122-125, 2012.
- 19) 川上 浩司. 薬剤疫学と薬理学. 日本薬理学会雑誌 (*Folia Pharmacol. Jpn.*), 140: 174-176, 2012.
- 20) 漆原 尚巳, 川上 浩司. 日本におけるオセルタミビルの処方と異常行動リスクに対する規制措置の影響 -保険薬局データベースを用いた医薬品使用実態調査. *インフルエンザ*, 13 (3) 37-43, 2012.
- 21) 川上 浩司. 創薬/創医療機器：なぜ私は海外に活路を求めるのか、なぜ私は日本に活路を見いだすのか-京都大学における開発型臨床試験と環境整備-. 慶應義塾大学シンポジウム. *臨床医薬*, 28 (8) : 665-678, 2012.
- 22) 川上 浩司. 薬剤疫学の課題. 最新医学, 67 (4) : 123-126, 2012.
- 23) 川上 浩司. 医薬品・医療機器の開発：現状と日本の問題点. 日本眼内レンズ

屈折手術学会誌 ( IOL&RS ) ,  
26 (1) 107-110, 2012.

- 24) 川上 浩司. 未承認医療機器を用いた臨床研究. 薬理と治療, 40: S23-S24, 2012.
- 25) 川上 浩司, 他 13 名. 「未承認医療機器を用いた臨床研究実施の手引き」抜粋版. 薬理と治療, 40: S48-S52, 2012.
- 26) 川上 浩司. 臨床試験にかかるキャリアパスを考える (第 2 回日本臨床試験研究会学術集会会長講演). 薬理と治療, 40: S38-S40, 2012.

【樋之津 史郎】

(英文原著)

- 1) Kita F, Hinotsu S, Yorifuji T, et al. Domperidone With ORT in the Treatment of Pediatric Acute Gastroenteritis in Japan: A Multicenter, Randomized Controlled Trial. *Asia Pac J Public Health*. 2012 Jan 10.
- 2) Onozawa M, Miyanaga N, Hinotsu S, et al. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer. *Jpn J Clin Oncol*. 2012 Sep;42 (9) :825-30.
- 3) Kitagawa Y, Hinotsu S, Shigehara K, et al. Japan Cancer of the Prostate Risk Assessment for combined androgen

blockade including bicalutamide: Clinical application and validation. *Int J Urol*. 2012 Dec 6. doi: 10.1111/iju.12037.

(H25)

【川上 浩司】

(英文原著)

1. Ueyama H, Hinotsu S, Tanaka S, Urushihara H, Nakamura M, Nakamura Y, Kawakami K. A survey of non-small cell lung cancer patients with meningeal carcinomatosis in Japan: incidence and medical resource consumption. *Advances in Pharmacoepidemiology and Drug Safety* 37(4):259-268, 2014..
2. Hamada S, Shibata A, Urushihara H, Sengoku S, Suematsu C, and Kawakami K. Transaction cost analysis of new drug application affairs in Japan: a case study of a multinational pharmaceutical company. *Therapeutic Innovation & Regulatory Science*, in press, 2014.
3. Yamauchi Y, Kawashima Y, Urushihara H, Kita F, Kobayashi Y, Hinotsu S, Nakagawa M, and Kawakami K. Survey to physician toward their understanding of regulatory environment of clinical trials in Japan. *General Medicine*,

- in press, 2014.
4. Onishi Y, Hinotsu S, Furukawa TA, and Kawakami K. Psychotropic prescription patterns among patients diagnosed with depressive disorder based on claims database in Japan. *Clinical Drug Investigation* 33(8):597-605, 2013.
  5. Takabayashi N, Urushihara H, and Kawakami K. Biased safety reporting in blinded randomized clinical trials: meta-analysis of angiotensin receptor blocker trials. *PLoS ONE* 8(9):e75027, 2013.
  6. Honjo Y, Horibe T, Ayaki T, Mori H, Komiya T, Takahashi R, and Kawakami K. Protein disulfide isomerase P5-immunopositive inclusions in patients with Alzheimer disease. *Journal of Alzheimer's Disease* 38(3):601-609, 2013.
  7. Ohara K, Kohno M, and Kawakami K. Localization of the anti-cancer peptide EGFR-lytic hybrid peptide in human pancreatic cancer BxPC-3 cells by immunohistochemistry. *Journal of Peptide Science* 19(8):511-515, 2013.
  8. Ohara K, Kohno M, Hamada T, and Kawakami K. Entry of a cationic lytic-type peptide into the cytoplasm via endocytosis-dependent and -independent pathways in human glioma U251 cells. *Peptides*, 50: 28-35, 2013.
  9. Furukawa TA, Onishi Y, Hinotsu S, Tajika A, Takeshima N, Shinohara K, Ogawa Y, Hayasaka Y, and Kawakami K. Prescription patterns following first-line SSRI/SNRIs for depression in Japan: a naturalistic cohort study based on a large claims database. *Journal of Affective Disorders* 150(3): 916-922, 2013.
  10. Hamada S, Hinotsu S, Ishiguro H, Toi M, and Kawakami K. Cross-national comparison of medical costs shared by payers and patients: a case of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees. *Breast Care* 8(4):282-288, 2013..
  11. Onishi Y, Hinotsu S, Nakao YM, Urushihara H, and Kawakami K. Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan. *Value in Health Regional Issues*, 2: 5-12, 2013.
  12. Seto K, Shoda J, Horibe T, Warabi E,

- Ishige K, Yamagata K, Kohno M, Yanagawa T, Bukawa H, and Kawakami K. Interleukin-4 receptor alpha-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma. *Oncology Reports*, 29: 2147-2153, 2013.
13. Tokumasu H, Hinotsu S, Kita F, and Kawakami K. Predictive value of clinical chorioamnionitis in extremely premature infants. *Pediatrics International*, 55: 35-38, 2013.
  14. Horibe T, Torisawa A, Akiyoshi R, Hatta-Ohashi Y, Suzuki H, and Kawakami K. Transfection efficacy of normal and cancer cell lines and monitoring of promoter activity by single-cell bioluminescence imaging. *Journal of Biological Chemical Luminescence*, DOI 10.1002/bio.2508, 2013.
  15. Ogawa A, Hinotsu S, and Kawakami K. Does late morning waking-up affect sleep during the following night in patients with primary insomnia? *Biological Rhythm Research*, 44: 938-948, 2013.
  16. Kawamoto M, Horibe T, Kohno M, and Kawakami K. HER2- targeted hybrid peptide that blocks HER2 tyrosine kinase, disintegrates cancer cell membrane and inhibits tumor growth in vivo. *Molecular Cancer Therapeutics*, 12: 384-393, 2013.
  17. Kawamoto M, Kohno M, Horibe T, Kawakami K. Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent. *Cancer Chemotherapy and Pharmacology*, 71: 799-807, 2013.
  18. Hiroi S, Sugiura K, Matsuno K, Hirayama M, Kuriyama K, Kaku K, and Kawakami K. A multicentre, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes. *Diabetes Technology and Therapeutics*, DOI10.1089/dia.2012.0246, 2013.
  19. Ohara K, Kohno M, Horibe T, and Kawakami K. Local drug delivery to a human pancreatic tumor via a newly designed multiple injectable needle. *Molecular and Clinical Oncology*, 1: 231-234, 2013.
- (著書および総説)
1. 川上 浩司. 「薬事申請を成功させる

ポイント：FDA 編」欧米中の薬事申請と関連書類事例。技術情報協会，pp260-266, 2013.

2. 川上 浩司. 「薬事から見た再生医療周辺技術とバイオマテリアル」幹細胞医療の実用化技術と産業展望（江上美芽・水谷 学監修）. シーエムシー出版, pp11-15, 2013.
3. 川上 浩司. （朝倉正紀企画：循環器病学における臨床研究-いかに確実に臨床に還元するか-）. 医学のあゆみ, 244（13）：1093-1097, 2013.
4. 川上 浩司. 医療イノベーションにおける創薬の出口戦略. 医薬ジャーナル増刊号「新薬展望 2013」. 49（s-1）25-29, 2013.

【田中 司朗】

- 1) Honyashiki M, Noma H, Tanaka S, Chen P, Ichikawa K, Ono M, Churchill R, Hunot V, Caldwell D, Furukawa TA. Specificity of CBT for depression: a contribution from multiple treatments meta-analyses. Cogn Ther Res 2014, in press.
- 2) Iguchi K, Hatano E, Yamanaka K, Tanaka S, Taura K, Uemoto S. The impact of posthepatectomy liver failure on the recurrence of hepatocellular carcinoma. World J Surg. 2014 Jan;38(1):150-8.

- 3) Katada H, Yukawa N, Urushihara H, Tanaka S, Mimori T, Kawakami K. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. Clinical Rheumatology 2015, 34(5):949-956.
- 4) Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, Ohara N, Matsunaga S, Yamada T, Hanyu O, Sone H. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014 Mar;15(3):202-14.
- 5) Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, Ohara N, Matsunaga S, Yamada T, Hanyu O, Sone H. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. Am J Cardiol. 2014 Mar 15;113(6):1058-65.
- 6) Marui A, Kimura T, Shiomi H, Tanaka S, Nishiwaki N, Hanyu M, Komiya T, Kita T, Sakata R, The CREDO-Kyoto PCI/CABG Registry Cohort-2. Three-year outcome after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure: From the CREDO-Kyoto PCI/CABG Registry Cohort-2. Eur J

- Cardiothorac Surg 2015, 47(2):316-321.
- 7) Minakata K, Tanaka S, Okawa Y, Shimamoto M, Kaneko T, Takahara Y, Yaku H, Yamanaka K, Usui A, Tamura N, Sakata R. Long-term Outcomes of the Carpentier-Edwards Pericardial Valve in the Aortic Position in Japanese Patients. *Circ J* 2014, 78(4):882-889.
  - 8) Ohnaka M, Marui A, Yamahara K, Minakata K, Yamazaki K, Kumagai M, Masumoto H, Tanaka S, Ikeda T, Sakata R. Effect of microRNA-145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype. *J Thorac Cardiovasc Surg*. 2014, 148(2):676-682.
  - 9) Sumi E, Yamazaki T, Tanaka S, Yamamoto K, Nakayama T, Bessho K, Yokode M. The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study. *Pharmacoepidemiol Drug Safety* 2014, 23(4):398-405.
  - 10) Tanaka S, Kuroda T, Sugimoto T, Nakamura T, Shiraki M. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide. *Curr Med Res Opin*. 2014, 30(5):931-936.
  - 11) Tanaka S, Fukinbara S, Tsuchiya S, Suganami H, Ito YM. Current practice for the prevention and treatment of missing data in confirmatory clinical trials: A survey of Japan-based and foreign-based pharmaceutical manufacturers in Japan. *Therapeutic Innovation & Regulatory Science* 2014, in press.
  - 12) Tanaka M, Ushijima K, Sung W, Kawakita M, Tanaka S, Mukai Y, Tamura K, Maruyama S. Association between social group participation and perceived health among elderly inhabitants of a previously methylmercury-polluted area. *Environ Health Prev Med* 2014, 19(4):258-264.
  - 13) Ueyama H, Hinotsu S, Tanaka S, Urushihara H, Nakamura M, Nakamura Y, Kawakami K. Application of a self-controlled case series study to a database study in children. *Drug Safety*, 2014, 37(4):259-268.
  - 14) Heianza Y, Arase Y, Saito K, Hsieh SD, Tsuji H, Kodama S, Tanaka S, Ohashi Y, Shimano H, Yamada N, Hara S, Sone H. Development of a screening score for undiagnosed

- diabetes and its application in estimating absolute risk of future type 2 diabetes in Japan: Toranomon Hospital Health Management Center Study 10 (TOPICS 10). *J Clin Endocrinol Metab.* 2013 Mar;98(3):1051-60.
- 15) Honda K, Sone M, Tamura N, Sonoyama T, Taura D, Kojima K, Fukuda Y, Tanaka S, Yasuno S, Fujii T, Kinoshita H, Ariyasu H, Kanamoto N, Miura M, Yasoda A, Arai H, Ueshima K, Nakao K. Adrenal reserve function after unilateral adrenalectomy in patients with primary aldosteronism. *J Hypertens.* 2013 Oct;31(10):2010-7
- 16) Horikawa C, Kodama S, Tanaka S, Fujihara K, Hirasawa R, Yachi Y, Shimano H, Yamada N, Saito K, Sone H. Diabetes and risk of hearing impairment in adults: a meta-analysis. *J Clin Endocrinol Metab.* 2013 Jan;98(1):51-8.
- 17) Horikawa C, Yoshimura Y, Kamada C, Tanaka S, Tanaka S, Takahashi A, Hanyu O, Araki A, Ito H, Tanaka A, Ohashi Y, Akanuma Y, Yamada N, Sone H. Dietary intake in Japanese patients with type 2 diabetes: Analysis from Japan Diabetes Complication Study. *J Diabete Invest* 5(2):176-187, 2013.
- 18) Kanematsu A, Tanaka S, Johnin K, Kawai S, Nakamura S, Imamura M, Yoshimura K, Higuchi Y, Yamamoto S, Okada Y, Nakai H, Ogawa O. A multi-center study of pediatric uroflowmetry data using patterning software. *J Pediatr Urol.* 2013 Feb;9(1):57-61.
- 19) Iguchi K, Hatano E, Yamanaka K, Tanaka S, Taura K, Uemoto S. The impact of posthepatectomy liver failure on the recurrence of hepatocellular carcinoma. *World J Surg* 2013, 38(1):150-158..
- 20) Ito-Ihara T, Hong J, Kim O, Sumi E, Kim S, Tanaka S, Narita K, Hatta T, Choi E, Choi K, Miyagawa T, Minami M, Murayama T, Yokode M. An international survey of physicians regarding clinical trials: A comparison between Kyoto University Hospital and Seoul National University Hospital. *BMC Med Res Methodol* 13:130, 2013.
- 21) Kasai Y, Hatano E, Iguchi K, Seo S, Taura K, Yasuchika K, Mori A, Kaido T, Tanaka S, Shibata T, Shibata T, Uemoto S. Prediction of remnant liver hypertrophy after preoperative portal vein embolization. *European Surgical Research* 51(3-4):129-137, 2013.
- 22) Kawasaki R, Tanaka S, Tanaka S, Abe

- S, Sone H, Yokote K, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N, Yamashita H; Japan Diabetes Complications Study Group. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. *Ophthalmology*. 2013 Mar;120(3):574-82.
- 23) Kodama S, Horikawa C, Fujihara K, Hirasawa R, Yachi Y, Yoshizawa S, Tanaka S, Sone Y, Shimano H, Iida KT, Saito K, Sone H. Use of high-normal levels of hemoglobin A1C and fasting plasma glucose for diabetes screening and prediction - A meta-analysis. *Diabetes Metab Res Rev*. 2013, 29(8):680-692.
- 24) Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, Ohara N, Matsunaga S, Yamada T, Hanyu O, Sone H. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. *Obes Rev*. 2014, 15(3):202-214.
- 25) Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, Saito K, Yamada N, Ohashi Y, Sone H. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: A meta-analysis. *Diabetes Care*. 2013 Feb;36(2):471-9.
- 26) Kodama S, Horikawa C, Yoshizawa S, Fujihara K, Yachi Y, Tanaka S, Suzuki A, Hanyu O, Yagyu H, Sone H. Body weight change and type 2 diabetes. *Epidemiology*. 2013 Sep;24(5):778-779.
- 27) Kuroda T, Tanaka S, Saito M, Shiraki Y, Shiraki M. Plasma level of homocysteine associated with severe vertebral fracture in postmenopausal women. *Calcif Tissue Int*. 2013 Sep;93(3):269-75.
- 28) Marui A, Okabayashi H, Komiya T, Tanaka S, Furukawa Y, Kita T, Kimura T, Sakata R; CREDO-Kyoto Investigators. Impact of occult renal impairment on early and late outcomes following coronary artery bypass grafting. *Interact Cardiovasc Thorac Surg*. 2013 Oct;17(4):638-43.
- 29) Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, Sone H, Yamashita H, Katayama S; for the Japan Diabetes Complications Study Group. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study (JDACS). *Diabetes Care*. 2013 Sep;36(9):2803-9.

- 30) Nose M, Kodama C, Ikejima C, Mizukami K, Matsuzaki A, Tanaka S, Yoshimura A, Yasuno F, Asada T. ApoE4 is not associated with depression when mild cognitive impairment is considered. *Int J Geriatr Psychiatry*. 2013 Feb;28(2):155-63.
- 31) Ohno S, Hinotsu S, Murata K, Tanaka S, Kawakami K. A survey of non-small cell lung cancer patients with meningeal carcinomatosis in Japan: Incidence and medical resource consumption. *Adv Pharmacoepidem Drug Safety* 2013;2:133.
- 32) Sone H, Tanaka S, Tanaka S, Suzuki S, Seino H, Hanyu O, Sato A, Toyonaga T, Okita K, Ishibashi S, Kodama S, Akanuma Y, Yamada N; on behalf of the Japan Diabetes Complications Study Group. Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDACS). *Diabetologia*. 2013, 56(5):1021-1030.
- 33) Tanaka S, Kuroda T, Saito M, Shiraki M. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women. *Osteoporos Int*. 2013 Jan;24(1):69-76.
- 34) Tanaka S, Kuroda T, Yamazaki Y, Shiraki Y, Yoshimura N, Shiraki M. Serum 25-hydroxyvitamin D below 25 ng/mL is a risk factor for long bone fracture comparable to bone mineral density in postmenopausal Japanese women. *J Bone Miner Metab* 2014, 32(5):514-523.
- 35) Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M. Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). *J Bone Miner Metab*, 2014, 32(3):298-304.
- 36) Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, Yamada N, Araki A, Ito H, Sone H, Ohashi Y; for the Japan Diabetes Complications Study Group; the Japanese Elderly Diabetes Intervention Trial Group. Predicting macro- and microvascular complications in type 2 diabetes: The Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. *Diabetes Care*. 2013 May;36(5):1193-9.

- 37) Tanaka S, Tanaka S, Imuro S, Yamashita H, Katayama S, Ohashi Y, Akanuma Y, Yamada N, Araki A, Sone H; on behalf of the Japan Diabetes Complications Study Group. Cohort Profiles: The Japan Diabetes Complications Study: a long-term follow-up of a randomised lifestyle intervention trial of type 2 diabetes. *Int J Epidemiol* 2014, 43(4):1054-1062.
- 38) Tanaka S, Uenishi K, Yamazaki Y, Kuroda T, Shiraki M. Low calcium intake is associated with high plasma homocysteine level in postmenopausal women. *J Bone Miner Metab* 2014, 32(3):317-323.
- 39) Tanaka S, Yoshimura Y, Kamada C, Tanaka S, Horikawa C, Okumura R, Ito H, Ohashi Y, Akanuma Y, Yamada N, Sone H; for the Japan Diabetes Complications Study Group. Intakes of dietary fiber, vegetables, and fruits and incidence of cardiovascular disease in Japanese patients with type 2 diabetes. *Diabetes Care* 2013;36:3916-22.
- 40) Tanaka S, Yoshimura Y, Kawasaki R, Kamada C, Tanaka S, Horikawa C, Ohashi Y, Araki A, Ito H, Akanuma Y, Yamada N, Yamashita H, Sone H; for the Japan Diabetes Complications Study Group. Fruit intake and incident diabetic retinopathy with type 2 diabetes. *Epidemiology*. 2013 Mar;24(2):204-11.
- 41) Togo Y, Tanaka S, Kanematsu A, Ogawa O, Miyazato M, Saito H, Arai Y, Hoshi A, Terachi T, Fukui K, Kinoshita H, Matsuda T, Yamashita M, Kakehi Y, Tsuchihashi K, Sasaki M, Ishitoya S, Onishi H, Takahashi A, Ogura K, Mishina M, Okuno H, Oida T, Horii Y, Hamada A, Okasyo K, Okumura K, Iwamura H, Nishimura K, Manabe Y, Hashimura T, Horikoshi M, Mishima T, Okada T, Sumiyoshi T, Kawakita M, Kanamaru S, Ito N, Aoki D, Kawaguchi R, Yamada Y, Kokura K, Nagai J, Kondoh N, Kajio K, Yoshimoto T, Yamamoto S. Antimicrobial prophylaxis to prevent perioperative infection in urological surgery: a multicenter study. *J Infect Chemother* 2013, 19(6):1093-1101.
- 42) Yamanaka K, Hatano E, Kanai M, Tanaka S, Yamamoto K, Narita M, Nagata H, Ishii T, Machimoto T, Taura K, Uemoto S. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. *Int J Clin Oncol* 2014, 19(3):485-489.
- 43) Yamazaki T, Yamori M, Tanaka S, Yamamoto K, Sumi E, Nishimoto-Sano M, Asai K, Takahashi K, Nakayama T, Bessho

K. Risk factors and indices of osteomyelitis of the jaw in osteoporosis patients: results from a hospital-based cohort study in Japan. *PLoS One*. 2013 Nov 1;8(11):e79376.

and Koji Kawakami. The membrane-lytic peptides K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure. *Chemistry and Biology*, 21: 1522-1532, 2014.

(H26)

【川上 浩司】

(論文原著英文)

1. Tomohisa Horibe, Eiji Warabi, Masayuki Kohno, Toru Yanagawa, Hiroki Bukawa, Yasuni Nakanuma, and Koji Kawakami. Targeting of Interleukin-4 receptor alpha by hybrid peptide for novel biliary tract cancer therapy. *International Journal of Hepatology*, Article ID 584650, 2014.
2. Arong Gaowa, Tomohisa Horibe, Masayuki Kohno, Yasuhiko Tabata, Hiroshi Harada, Masahiro Hiraoka, and Koji Kawakami. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers. *European Journal of Pharmaceutics and Biopharmaceutics*, 92: 228-236, 2015.
3. Masayuki Kohno, Tomohisa Horibe, Koji Ohara, Shinji Ito, and Koji Kawakami. The membrane-lytic peptides K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure. *Chemistry and Biology*, 21: 1522-1532, 2014.
4. Hisashi Urushihara, Shingo Kobayashi, Yasuyuki Honjo, Shinji Kosugi, and Koji Kawakami. Utilization of antipsychotic drugs in elderly patients with Alzheimer's disease in ambulatory practice in Japan. *Science Postprint*, 1(1): e00014. doi:10.14340/spp.2014.01C0003, 2014.
5. Kyoko Murata, Shiro Hinotsu, Shota Hamada, Yasumasa Ezoe, Manabu Muto, and Koji Kawakami. The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study. *BMC Health Service Research*, DOI 10.1186/s12913-015-0734-2, 2015.
6. Tomohisa Horibe, Aya Torisawa, Masayuki Kohno, and Koji Kawakami. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of

- Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide. *BMC Cancer*, 14:615, 2014.
7. Shota Hamada, Shiro Hinotsu, Koji Kawai, Shigeyuki Yamada, Shintaro Narita, Koji Yoshimura, Hiroyuki Nishiyama, Yoichi Arai, Tomonori Habuchi, Osamu Ogawa, and Koji Kawakami. Antimetabolic efficacy and safety of a combination of palonosetron, aprepitant and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. *Supportive Care in Cancer*, 22: 2161-2166, 2014.
  8. Arong Gaowa, Tomohisa Horibe, Masayuki Kohno, Keisuke Sato, Hiroshi Harada, Masahiro Hiraoka, Yasuhiko Tabata, and Koji Kawakami. Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled-release and enhancement of anti tumor activity *in vivo*. *Journal of Controlled Release*, 176: 1-7, 2014.
  9. Masayuki Kohno, Koji Ohara, Tomohisa Horibe, and Koji Kawakami. Inhibition of neurite outgrowth by a neuropilin-1 binding peptide derived from semaphorin 3A. *International Journal of Peptide Research and Therapeutics*, 20: 153-160, 2014.
  10. Hirotaka Katada, Naoichiro Yukawa, Hisashi Urushihara, Shiro Tanaka, Tsuneyo Mimori, and Koji Kawakami. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. *Clinical Rheumatology*, doi 10.1007/s10067-013-2482-1, 2014.
  11. Shota Hamada, Yukie Yamauchi, Osamu Miyake, Motoko Nakayama, Haruko Yamamoto, and Koji Kawakami. Current environment for conducting clinical researches with medical devices in hospitals in Japan. *Journal of Clinical Trials*, 4: 153. doi:10.4172/2167-0870.1000153, 2014.
  12. Shota Hamada, Akiko Shibata, Hisashi Urushihara, Shintaro Sengoku, Chihiro Suematsu, and Koji Kawakami. Transaction cost analysis of new drug application affairs in Japan: a case study of a multinational pharmaceutical company. *Therapeutic Innovation*

- & *Regulatory Science*, 48: 371-377, 2014
13. Hanae Ueyama, Shiro Hinotsu, Shiro Tanaka, Hisashi Urushihara, Masaki Nakamura, Yuji Nakamura, and Koji Kawakami. Application of a self-controlled case series study to a database study in children. *Drug Safety*, 37: 259-268, 2014.
  14. Hisashi Urushihara and Koji Kawakami. Impacts of introducing the Investigational New Drug system. *Therapeutic Innovation and Regulatory Science*, 48: 463-472, 2014.
- (論文原著和文)
15. 錦織 達人, 川上 浩司, 後藤 励, 肥田 侯矢, 坂井 義治. 外科領域における Health Technology Assessment. 日本外科学会雑誌, 116 (1) :64-69, 2015.
- (著書および総説)
1. 川上 浩司. 「医療分野における疫学研究によるビッグデータ解析事例」ビッグデータの収集、調査、分析と活用事例. 技術情報協会, pp245-248, 2014.
  2. 川上 浩司. 「製品種別ごとのデータ・情報の取得とまとめ方のポイント: 核酸医薬, 遺伝子治療薬, 細胞治療薬における留意点」医薬品/医療機器の承認申請書の上手な書き方・まとめ方-審査に不可欠なデータ・情報の取得の仕方. 技術情報協会, pp346-348, 2014.
  3. 川上 浩司. 「薬剤疫学の課題と展望」「比較有効性研究」臨床研究のススメ. 井村裕夫監修. 最新医学社, pp141-146, pp185-192, 2014.
  4. Shiro Tanaka, Sachiko Tanaka, and Koji Kawakami. Statistical issues in observational studies in oncology in the era of big data. *Japanese Journal of Clinical Oncology*, 45(4):323-327, 2015.
  5. Yoko M. Nakao and Koji Kawakami. Abdominal obesity: why it matters. *Journal of Obesity & Weight loss Therapy*, 4: e111.doi:10.4172/2165-7904.100e111, 2014.
  6. Yoko Uryuhara and Koji Kawakami. The contribution of pharmaceuticals in the history of organ transplantation. *Pharmaceutica Analytica Acta*, 5: 277. doi: 10.4172/2153-2435.1000277, 2014.
  7. 川上 浩司. 医療技術と薬剤の評価に関する国際動向. 血液内科,

68 (4) 548-551, 2014.

8. 川上 浩司. 医療や看護における臨床及び経済評価. 日本糖尿病教育・看護学会誌, 18 (1) 56-59, 2014.

9. 村田 京子, 川上 浩司. 分子標的薬・コンパニオン診断薬の医療技術評価の現状と課題 (登勉企画: コンパニオン診断-診断薬開発から承認審査、臨床応用へ). 医学のあゆみ, 248 (11) 857-860, 2014.

【田中 司朗】

(論文英文)

1. Furukawa TA, Levine SZ, Tanaka S, Goldberg T, Samara M, Davis JM, Cipriani A, Leucht S. Initial severity and efficacy of antipsychotics for schizophrenia: Individual participant level analyses of six placebo-controlled studies. JAMA Psychiatry. 2015;72(1):14-2.

2. Heianza Y, Arase Y, Kodama S, Tsuji H, Tanaka S, Saito K, Hara S, Sone H. Trajectory of Body Mass Index Before the Development of Type 2 Diabetes in Japanese Men: Toranomon Hospital Health Management Center Study 15 (TOPICS 15). J Diabetes Invest 2015, published online

3. Kido A, et al. Pretreatment mean apparent diffusion coefficient is significantly correlated with event-free survival in patients with FIGO stages Ib to IIIb cervical cancer. Int J Gynecological Cancer 2015, in press.

4. Marui A, Kimura T, Nishiwaki N, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Three-year outcomes after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure: from the CREDO-Kyoto percutaneous coronary intervention/coronary artery bypass graft registry cohort-2. Eur J Cardiothorac Surg. 2015 Feb;47(2):316-21

5. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; The CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Five-Year Outcomes of Percutaneous Versus Surgical Coronary Revascularization in Patients With Diabetes Mellitus (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2015, published online.

6. Minakata K, Tanaka S, Takahara Y, Kaneko T, Usui A, Shimamoto M, Okawa Y, Yaku H, Yamanaka K, Tamura N, Sakata R. Long-term Durability of Pericardial Valves in the Aortic Position in Younger Patients: When does Reoperation Become Necessary? *J Cardiac Surgery* 2015, in press.
7. Osada H, Marui A, Tanaka S, Meshii K, Ohnaka M, Nakajima H. Acute subdural hematoma after aortic surgery: A retrospective comparative study. *Asian Cardiovasc Thorac Ann.* 2015 Jan;23(1):24-30.
8. Saida S, Watanabe K, Kato I, Fujino H, Umeda K, Okamoto S, Uemoto S, Hishiki T, Yoshida H, Tanaka S, Adachi S, Niwa A, Nakahata T, Heike T. Prognostic significance of Aminopeptidase-N (CD13) in hepatoblastoma. *Pediatrics Int* 2015, in press.
9. Takizawa O, Urushibara H, Tanaka S, Kawakami K. Price difference as a predictor of the selection between brand name and generic statins in Japan. *Health Policy* 2015, in press.
10. Tanaka S, Tanaka S, Kawakami K. Methodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data. *Jpn J Clin Oncol* 2015, published online.
11. Aihara T, Tanaka S, Sagara Y, Iwata H, Hozumi Y, Takei H, Yamaguchi H, Ishitobi M, Egawa C. Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. *Breast Cancer.* 2014 May;21(3):284-91.
12. Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, Tanaka S, Kodama S, Hara S, Sone H. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). *J Clin Endocrinol Metab.* 2014 Aug;99(8):2952-60.
13. Heianza Y, Kato K, Fujihara K, Tanaka S, Kodama S, Hanyu O, Sato K, Sone H. Role of sleep duration as a risk factor for Type 2 diabetes among adults of different ages in Japan: the Niigata

- Wellness Study. *Diabet Med*. 2014 Nov;31(11):1363-7.
14. Heianza Y, Kato K, Kodama S, Suzuki A, Tanaka S, Hanyu O, Sato K, Sone H. Stability and changes in metabolically healthy overweight or obesity and risk of future diabetes: Niigata wellness study. *Obesity* 2014 Nov;22(11):2420-5.
  15. Heianza Y, Kato K, Matsunaga S, Kodama S, Suzuki A, Fujihara K, Tanaka S, Hanyu O, Sato K, Sone H. Risk of the development of type 2 diabetes in relation to overall obesity, abdominal obesity and the clustering of metabolic abnormalities in Japanese individuals—Does metabolically healthy overweight really exist?: Niigata Wellness Study. *Diabet Med* 2014, in press.
  16. Heianza Y, Kodama S, Arase Y, Hsieh SD, Yoshizawa S, Tsuji H, Saito K, Tanaka S, Hara S, Sone H. Role of body mass index history in predicting risk of the development of hypertension in Japanese individuals: Toranomon Hospital Health Management Center Study 18 (TOPICS 18). *Hypertension*. 2014 Aug;64(2):247-52.
  17. Heianza Y, Suzuki A, Fujihara K, Tanaka S, Kodama S, Hanyu O, Sone H. Impact on short-term glycaemic control of initiating diabetes care versus leaving diabetes untreated among individuals with newly screening-detected diabetes in Japan. *J Epidemiol Community Health*. 2014 Dec;68(12):1189-95.
  18. Honyashiki M, Noma H, Tanaka S, Chen P, Ichikawa K, Ono M, Churchill R, Hunot V, Caldwell D, Furukawa TA. Specificity of CBT for depression: a contribution from multiple treatments meta-analyses. *Cogn Ther Res* 2014;38:249-260.
  19. Horikawa C, Kodama S, Fujihara K, Yachi Y, Tanaka S, Suzuki A, Hanyu O, Shimano H, Sone H. Association of Helicobacter pylori infection with glycemic control in patients with diabetes: a meta-analysis. *J Diabetes Res*. 2014;2014:250620.
  20. Horikawa C, Yoshimura Y, Kamada C, Tanaka S, Tanaka S, Hanyu O, Araki A, Ito H, Tanaka A, Ohashi Y, Akanuma Y, Yamada N, Sone H; Japan Diabetes Complications Study Group. Dietary sodium intake and incidence of diabetes complications

- in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDACS). *J Clin Endocrinol Metab.* 2014 Oct;99(10):3635-43.
21. Horikawa C, Yoshimura Y, Kamada C, Tanaka S, Tanaka S, Takahashi A, Hanyu O, Araki A, Ito H, Tanaka A, Ohashi Y, Akanuma Y, Yamada N, Sone H. Dietary intake in Japanese patients with type 2 diabetes: Analysis from Japan Diabetes Complications Study. *J Diabetes Investig.* 2014 Mar 23;5(2):176-87.
22. Iguchi K, Hatano E, Yamanaka K, Tanaka S, Taura K, Uemoto S. The impact of posthepatectomy liver failure on the recurrence of hepatocellular carcinoma. *World J Surg.* 2014 Jan;38(1):150-8.
23. Katada H, Yukawa N, Urushihara H, Tanaka S, Mimori T, Kawakami K. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. *Clin Rheumatol* 2014, published online.
24. Sone H. Quantitative Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, Ohara N, Matsunaga S, Yamada T, Hanyu O, relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. *Obes Rev.* 2014 Mar;15(3):202-14.
25. Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, Ohara N, Matsunaga S, Yamada T, Hanyu O, Sone H. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. *Am J Cardiol.* 2014 Mar 15;113(6):1058-65.
26. Komiya T, Ueno G, Kadota K, Mitsudo K, Okabayashi H, Nishiwaki N, Hanyu M, Kimura T, Tanaka S, Marui A, Sakata R and the CREDO-Kyoto Investigators. An optimal strategy for coronary revascularization in patients with severe renal dysfunction. *Eur J Cardiothorac Surg* 2014, published online.
27. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients

- with end-stage renal disease requiring dialysis (Five-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). *Am J Cardiol.* 2014 Aug 15;114(4):555-61.
28. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions  $\leq 50\%$  versus  $> 50\%$  (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). *Am J Cardiol.* 2014 Oct 1;114(7):988-96.
29. Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. *Haematologica.* 2014 Nov;99(11):e225-7.
30. Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. *Blood Cancer J.* 2014 Jul 11;4:e226.
31. Minakata K, Bando K, Tanaka S, Takanashi S, Konishi H, Miyamoto Y, Ueshima K, Yasuno S, Ueda Y, Okita Y, Masuda I, Okabayashi H, Yaku H, Okamura Y, Tanemoto K, Arinaga K, Hisashi Y, Sakata R. Preoperative chronic kidney disease as a strong predictor of postoperative infection and mortality after coronary artery bypass grafting. *Circ J.* 2014 Aug 25;78(9):2225-31.
32. Minakata K, Tanaka S, Okawa Y, Shimamoto M, Kaneko T, Takahara Y, Yaku H, Yamanaka K, Usui A, Tamura N, Sakata R. Long-term outcome of the carpentier-edwards pericardial valve in the aortic position in

- Japanese patients. *Circ J*. 2014;78(4):882-9.
33. Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K. Diagnostic Value of (18)F-FDG PET/CT and MRI in Predicting the Clinicopathologic Subtypes of Invasive Breast Cancer. *AJR Am J Roentgenol*. 2014 Aug;203(2):272-9.
34. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, Cipriani A, Geddes JR, Kanba S. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A network meta-analysis. *Lancet Psychiatry* 2014;1(1):351-9.
35. Nakagawa T, Kumakawa K, Usami S, Hato N, Tabuchi K, Takahashi M, Fujiwara K, Sasaki A, Komune S, Sakamoto T, Hiraumi H, Yamamoto N, Tanaka S, Tada H, Yamamoto M, Yonezawa A, Ito-Ihara T, Ikeda T, Shimizu A, Tabata Y, Ito J. A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. *BMC Med*. 2014 Nov 19;12(1):219.
36. Noma H, Tanaka S. Analysis of case-cohort designs with binary outcomes: Improving efficiency using whole-cohort auxiliary information. *Statist Method Med Res* 2014, in press.
37. Ohnaka M, Marui A, Yamahara K, Minakata K, Yamazaki K, Kumagai M, Masumoto H, Tanaka S, Ikeda T, Sakata R. Effect of microRNA-145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype. *J Thorac Cardiovasc Surg*. 2014 Aug;148(2):676-82.e2.
38. Sumi E, Yamazaki T, Tanaka S, Yamamoto K, Nakayama T, Bessho K, Yokode M. The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study. *Pharmacoepidemiol Drug Saf*. 2014 Apr;23(4):398-405.
39. Tanaka S, Fukinbara S, Tsuchiya S, Suganami H, Ito YM. Current practice for the prevention and treatment of missing data in confirmatory clinical trials: A

- survey of Japan-based and foreign-based pharmaceutical manufacturers in Japan. *Therapeutic Innovation & Regulatory Science* 2014;48(6):717-23.
40. **Tanaka S**, Kuroda T, Sugimoto T, Nakamura T, Shiraki M. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide. *Curr Med Res Opin.* 2014 May;30(5):931-6.
41. **Tanaka S**, Kuroda T, Yamazaki Y, Shiraki Y, Yoshimura N, Shiraki M. Serum 25-hydroxyvitamin D below 25 ng/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women. *J Bone Miner Metab.* 2014 Sep;32(5):514-23.
42. **Tanaka S**, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M. Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). *J Bone Miner Metab.* 2014 May;32(3):298-304.
43. **Tanaka S**, Tanaka S, Iimuro S, Akanuma Y, Ohashi Y, Yamada N, Araki A, Ito H, Sone H; for the Japan Diabetes Complications Study Group and the Japanese Elderly Diabetes Intervention Trial Group. Body mass index and mortality among Japanese patients with type 2 diabetes: Pooled analysis of the Japan Diabetes Complications Study and the Japanese Elderly Diabetes Intervention Trial. *J Clin Endocrinol Metab.* 2014 Dec;99(12):E2692-6
44. **Tanaka S**, Tanaka S, Iimuro S, Yamashita H, Katayama S, Ohashi Y, Akanuma Y, Yamada N, Sone H; Japan Diabetes Complications Study Group. Cohort Profile: The Japan Diabetes Complications Study: a long-term follow-up of a randomised lifestyle intervention study of type 2 diabetes. *Int J Epidemiol.* 2014 Aug;43(4):1054-62.
45. **Tanaka S**, Uenishi K, Ishida H, Takami Y, Hosoi T, Kadowaki T, Orimo H, Ohashi Y. A randomized intervention trial of 24-week dairy consumption on waist circumference, blood pressure, and fasting blood sugar and lipids in Japanese men with the metabolic syndrome. *J Nutr Sci Vitaminol* 2014, in press.